Welcome to Simcyp


population based pharmacokinetic modelling and simulation

home > research & development > publications > citations


Citations

Simcyp Citations RSS

Please view our latest citations below:


  • Pithavala, YK et al.

    Feb 2012

    Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
    Investigational New Drugs
    30, 273-281, February 2012

    More info

  • Plowchalk DR & Rowland-Yeo K

    Jan 2012

    Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
    European Journal of Clinical Pharmacology
    E-Publication Ahead Of Print, 2012

    More info

  • Bouzom F et al.

    Jan 2012

    Physiologically Based PharmacoKinetic (PBPK) modelling tools: how to fit with our needs?
    Biopharmaceutics & Drug Disposition
    E-Publication Ahead Of Print, 2012

    More info

  • Chen Y et al.

    Jan 2012

    Application of IVIVE and PBPK modelling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
    Biopharmaceutics and Drug Disposition
    E-Publication Ahead Of Print, 2012

    More info

  • Boulenc X et al.

    Jan 2012

    Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
    Drug Metabolism & Disposition
    40, 187-197, January 2012

    More info

  • Harrison A et al.

    Jan 2012

    Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.
    Xenobiotica
    42, 57-74, January 2012

    More info

  • Shaffer CL et al.

    Dec 2011

    Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
    Biopharmaceutics & Drug Disposition
    E-Publication Ahead Of Print, 2011

    More info

  • Jayaraman R et al.

    Dec 2011

    Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Drug Metabolism & Disposition
    39, 2219-2232, December 2011

    More info

  • Chappell JC et al.

    Dec 2011

    Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.
    European Journal of Clinical Pharmacology
    E-Publication Ahead Of Print, 2011

    More info

  • Tortorici MA et al.

    Dec 2011

    Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
    Investigational New Drugs
    29, 1370-1380, December 2011

    More info

  • Damle B

    Nov 2011

    Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.
    Antimicrobial Agents & Chemotherapy
    55, 5172-7177, November 2011

    More info

  • Ogilvie BW et al.

    Nov 2011

    The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Drug Metabolism & Disposition
    39, 2020-2033, November 2011

    More info

  • Chen Y et al.

    Nov 2011

    Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocyte and assessment of human drug-drug interactions.
    Drug Metabolism and Disposition
    39, 2085-2092, November 2011

    More info

  • Friedman EJ et al.

    Nov 2011

    Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Journal of Clinical Pharmacology
    51, 1561-1570, November 2011

    More info

  • Berry LM et al.

    Nov 2011

    Species differences in distribution and prediction of human Vss from preclinical data.
    Drug Metabolism and Disposition
    39, 2103-2116, November 2011

    More info

  • Jornil J et al.

    Oct 2011

    Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
    European Journal of Pharmaceutical Sciences
    44, 265-272, October 2011

    More info

  • Malhotra B et al.

    Aug 2011

    Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
    British Journal of Clinical Pharmacology
    72 , 263-269, August 2011

    More info

  • Wattanachai N et al.

    Aug 2011

    In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6a-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.
    European Journal of Clinical Pharmacology
    67, 815-824, August 2011

    More info

  • Xu Y et al.

    Jul 2011

    Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
    Drug Metabolism & Disposition
    39, 1139-1148, July 2011

    More info

  • Sinha VK et al.

    May 2011

    Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Clinical Pharmacokinetics
    50, 307-318, May 2011

    More info

  • Miyagi SJ & Collier AC

    May 2011

    The development of UGT1A1 and 1A6 in the pediatric liver.
    Drug Metabolism & Disposition
    39, 912-919, May 2011

    More info

  • Rekic D et al.

    Apr 2011

    In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    British Journal of Clinical Pharmacology
    71, 536-543, April 2011

    More info

  • Judson RS et al.

    Apr 2011

    Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment.
    Chem Res Toxicol
    24, 451-462, April 2011

    More info

  • Chen Y et al.

    Mar 2011

    Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
    Drug Metabolism and Disposition
    39, 373-382, March 2011

    More info

  • Nettleton DO & Einolf HJ

    Feb 2011

    Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
    Current Topics in Medicinal Chemistry
    11, 382-403, February 2011

    More info

  • Gandelman K et al.

    Feb 2011

    Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
    Journal of Clinical Pharmacology
    51, 229-236, February 2011

    More info

  • Idkaidek N & Arafat T

    Jan 2011

    Effect of microgravity on the pharmacokinetics of ibuprofen in humans.
    J Clin Pharmacol
    51, 1685-1689, December 2011

    More info

  • Guest EJ et al.

    Jan 2011

    Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
    British Journal of Clinical Pharmacology
    71, 72-87, January 2011

    More info

  • Guest EJ et al.

    Dec 2010

    Critique of the two-fold measure of prediction success for ratios:
    application for the assessment of drug-drug interactions.
    Drug Metabolism & Disposition
    39, 170-173, December 2010

    More info

  • Zhao P et al.

    Dec 2010

    Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Clinical Pharmacology & Therapeutics
    89, 259-267, December 2010

    More info

  • Motta P et al.

    Dec 2010

    Casopitant: in-vitro data and SimcypTM simulation to predict in-vivo metabolic interactions involving Cytochrome P450 3A4.
    Drug Metabolism & Disposition
    39, 363-372, December 2010

    More info

  • Sinha VK et al.

    Nov 2010

    Prediction of oral absorption and drug drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling.
    PSWC / AAPS Meeting
    New Orleans, USA, 13th-19th November 2010

  • Jin JY et al.

    Nov 2010

    Use of the Simcyp Population-Based ADME Simulator in early drug development: examples.
    PSWC / AAPS Meeting
    New Orleans, USA, 13th-19th November 2010

  • Venkatakrishnan K

    Nov 2010

    A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Clinical Pharmacokinetics
    49, 703-727, November 2010

    More info

  • Rotroff DM et al.

    Oct 2010

    Incorporating human dosimetry and exposure into high-throughput In vitro toxicity screening.
    Toxicological Sciences
    117, 348-358, October 2010

    More info

  • Shaffer CL et al.

    Sep 2010

    Using Simcyp® to project human oral pharmacokinetic variability in lead development to mitigate mechanism-based adverse events in the clinic.
    9th International ISSX Meeting
    Istanbul, Turkey, September 4th-8th 2010

  • Wang YH

    Jul 2010

    Confidence assessment of predicting clinical drug interactions of mechanism-based CYP3A inhibitors using Simcyp time-based approach and a static mathematic model.
    Drug Metabolism & Disposition
    38, 1094-1104, July 2010

    More info

  • Foti RS et al.

    Jun 2010

    Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
    Drug Metabolism and Disposition
    38, 981-987, June 2010

    More info

  • Polasek TM et al.

    Mar 2010

    In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
    European Journal of Clinical Pharmacology
    66, 275-283, March 2010

    More info

  • Jornil J et al.

    Mar 2010

    Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
    Drug Metabolism & Disposition
    38, 376-385, March 2010

    More info

  • Berry LM et al.

    Jan 2010

    Prediction of V(ss) from in vitro tissue binding studies.
    Drug Metabolism & Disposition
    38, 115-121, January 2010

    More info

  • Xu L et al.

    Dec 2009

    Prediction of human drug and drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Drug Metabolism & Disposition
    37, 2330-2339, December 2009

    More info

  • Caldwell GW et al.

    Nov 2009

    ADME optimization and toxicity assessment in early- and late-phase drug discovery.
    Current Topics in Medicinal Chemistry
    9, 965-980, 2009

    More info

  • Wong H et al.

    Nov 2009

    Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Xenobiotica
    39, 850-861, November 2009

    More info

  • Polasek TM et al.

    Oct 2009

    Assessment of inter-individual variability in predicted phenytoin clearance.
    European Journal of Clinical Pharmacology
    65, 1203-1210, December 2009

    More info

  • Espié P et al.

    Oct 2009

    Physiologically based pharmacokinetics (PBPK).
    Drug Metabolism Reviews
    41, 391-407, 2009

    More info

  • De Groot MJ et al.

    Oct 2009

    Understanding CYP2D6 interactions.
    Drug Discovery Today
    14, 964-972, October 2009

    More info

  • Foti RS et al.

    Sep 2009

    In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract.
    Drug Metabolism & Disposition
    37, 1848-1855, September 2009

    More info

  • Fahmi OA et al.

    Aug 2009

    Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Drug Metabolism & Disposition
    37, 1658-1666, August 2009

    More info

  • Gibson CR et al.

    Aug 2009

    Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.
    Xenobiotica
    39, 637-648, September 2009

    More info

  • Grimm SW et al.

    Jul 2009

    The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America (PhRMA).
    Drug Metabolism & Disposition
    37, 1355-1370, July 2009

    More info

  • Chu V et al.

    Jul 2009

    In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.
    Drug Metabolism & Disposition
    37, 1339-1354, July 2009

    More info

  • Hyland R et al.

    Apr 2009

    In vitro and in vivo glucuronidation of midazolam in humans.
    British Journal of Clinical Pharmacology
    67, 445-454, April 2009

    More info

  • Emoto C et al.

    Mar 2009

    Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding.
    Xenobiotica
    39, 227-235, March 2009

    More info

  • Summerfield S & Jeffrey P

    Mar 2009

    Discovery DMPK: changing paradigms in the eighties, nineties and noughties.
    Expert Opinion on Drug Discovery
    4, 207-218, 2009

    More info

  • Thelingwani RS et al.

    Mar 2009

    In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
    Drug Metabolism & Disposition
    37, 1286-1294, June 2009

    More info

  • Badwan A et al.

    Mar 2009

    Enhancement of oral bioavailability of insulin in humans.
    Neuro Endocrinology Letters
    30, 74-78, March 2009

    More info

  • Zhao P et al.

    Feb 2009

    Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
    Journal of Clinical Pharmacology
    49, 351-359, March 2009

    More info

  • Grime KH et al.

    Feb 2009

    Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    European Journal of Pharmaceutical Sciences
    36, 175-191, February 2009

    More info

  • Bouzom F & Walther B

    Dec 2008

    Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
    Fundamentals of Clinical Pharmacology

    22, 579-587, December 2008

    More info

  • Hyland R et al.

    Oct 2008

    Maraviroc: in vitro assessment of drug-drug interaction potential.
    British Journal of Clinical Pharmacology

    66, 498-507, October 2008

    More info

  • Westerhoff HV et al.

    Sep 2008

    Integrating systems approaches into pharmaceutical sciences.
    European Journal of Pharmaceutical Sciences
    35, 1-4, September 2008

    More info

  • Karalis V et al.

    Aug 2008

    Bioavailability and bioequivalence: focus on physiological factors and variability.
    Pharmaceutical Research
    25, 1956-1962, August 2008

    More info

  • Fowler S & Zhang H

    Jun 2008

    In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.
    The AAPS Journal
    10, 410-424, June 2008

    More info

  • McGinnity DF et al.

    Jun 2008

    Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
    Drug Metabolism & Disposition
    36, 1126-1134, June 2008

    More info

  • Youdim KA et al.

    May 2008

    Application of CYP3A4 in vitro data to predict clinical drug-drug interactions: predictions of compounds as objects of interaction.
    British Journal of Clinical Pharmacology
    65, 680-692, May 2008

    More info

  • Dong JQ et al.

    Mar 2008

    Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration.
    Current Computer-Aided Drug Design
    4, 54-66, March 2008

    More info

  • Foti RS et al.

    Mar 2008

    Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
    Xenobiotica
    38, 264-280, March 2008

    More info

  • Rakhit A et al.

    Jan 2008

    The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Simcyp) predicts in vivo metabolic inhibition.
    European Journal of Clinical Pharmacology
    64, 31-41, January 2008

    More info

  • De Buck SS & Mackie CE

    Dec 2007

    Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    Expert Opinion on Drug Metabolism & Toxicology
    3, 865-878, December 2007

    More info

  • Einolf HJ

    Oct 2007

    Comparison of different approaches to predict metabolic drug-drug interactions.
    Xenobiotica
    37, 1257-1294, October-November 2007

    More info

  • Riley RJ et al.

    Feb 2007

    Time-dependent CYP inhibition.
    Expert Opinion on Drug Metabolism & Toxicology
    3, 51-66, February 2007

    More info

  • Ekins S et al.

    Apr 2005

    Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity.
    Trends in Pharmacological Science
    26, 202-209, April 2005

    More info

  • Wishart DS

    Mar 2005

    Bioinformatics in drug development and assessment.
    Drug Metabolism Reviews
    37, 279-310, 2005

    More info

box top

Workshops


Please click here to view our upcoming workshops.
see more
Need more help?

Consortium members and associates include: